Key Conference Participation in September 2026

Poolbeg Pharma PLC

03 September 2026

 

Poolbeg Pharma plc

Poolbeg Pharma to Participate in Key Conferences in September 2026

Poolbeg Pharma to showcase POLB 001 at leading scientific and investor conferences

3 September 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has been selected to present at a number of leading international conferences this September.

All-Ireland Clinical AI Congress & AI Tech Expo

A new national healthcare conference dedicated to the practical adoption of artificial intelligence across the Irish healthcare system.

Title: AI in Drug Development: A Practical Case Study from an Industry Perspective

Presenter: Liam Tremble, Principal Scientist

Date & time: 12 September 2026, 11:15am BST

Location: O'Reilly Hall at University College Dublin, Belfield, Dublin 4

28^th Annual H.C. Wainwright Global Investment Conference

A leading investor conference bringing together public and private companies, institutional investors and industry leaders for corporate presentations, one-on-one meetings and networking opportunities.

Presenters: Jeremy Skillington, PhD, Chief Executive Officer and Ian O'Connell, Chief Financial Officer

Date & time: The presentation will be available on demand from 11 September 2026, 7:00am EST / 12:00pm BST

Location: Lotte New York Palace Hotel in New York

Meetings: Management will be available at the conference in New York for in-person one-on-one meetings with investors on 14-16 September 2026. To schedule a meeting, investors should contact their H.C. Wainwright representative or contact Poolbeg directly at [e-mail].

BIOShanghai Week 2026

BIOShanghai Week is a leading life sciences and biotechnology conference in China, bringing together global biopharma leaders, investors and innovators to explore industry trends, scientific advances and opportunities for collaboration and partnering.

Presentation title: From China to Europe: Raglan Capital - Sharing Experience, Building Partnerships in Biotech

Presenter: Cathal Friel, Executive Chair

Date & time: 18 September 2026

Location: Zhangjiang Science Hall, Pudong New Area, Shanghai, China

Investor Summit 2026

A leading UK investment conference bringing together 450+ private investors, CEOs, fund managers and finance professionals for a full day of expert insights, company presentations, panel discussions and networking.

Panel title: The Importance of Partnering to the Pharmaceutical Industry: The POLB 001 Opportunity

Panellists: Jeremy Skillington, PhD (CEO, Poolbeg Pharma), Chris Grimes-Crompton (Partner, Global Value and Access, Acumetis Global) & Michiel Bröker (Global Head of Pharma / Healthcare EMEA, UBS)

Moderated by: Ed Bowsher (Freelance journalist and investor)

Date & time: 18 September 2026, 13:40pm BST

Location: Upper Sugar Track, The Brewery, Chiswell Street, London, EC1Y 4SA

International Myeloma Society Annual Meeting

The International Myeloma Society Meeting is the premier global scientific conference in myeloma with a focus on basic, preclinical, and clinical aspects of disease. It brings together leading clinicians, academics, and pharmaceutical representatives to tackle the most pressing challenges in myeloma.

Poster title: POLB 001, an oral p38 MAPK inhibitor for the prevention of cytokine release syndrome

Presenter: Liam Tremble, Principal Scientist

Date & time: 24 September 2026, 12.00 - 13.00pm BST

Session: Session 1: Plenary. Global and National Perspectives on AI in Healthcare

Location: Scottish Events Campus, Glasgow, Scotland

If you would like to meet the Poolbeg team at any of the above events, please contact us at [e-mail].

Enquiries

Poolbeg Pharma Plc   Jeremy Skillington, CEO   Ian O'Connell, CFO	[phone]  [e-mail]
Cavendish Capital Markets Ltd (NOMAD & Joint Broker)   Geoff Nash, Trisyia Jamaludin (Corporate Finance)  Nigel Birks (Life Science Specialist Sales)  Harriet Ward (ECM)	[phone]
Oak Securities (Joint Broker)  Jerry Keen	[phone]
Shore Capital Stockbrokers Ltd (Joint Broker)  David Coaten, Harry Davies-Ball (Corporate Advisory)  Malachy McEntyre (Corporate Broking)	[phone]
J&E Davy (Joint Broker)   Anthony Farrell, Niall Gilchrist	[phone]
Optimum Strategic Communications   Nick Bastin, Katie Flint, Henry Williams	[phone]   [e-mail]

About Poolbeg Pharma plc 

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs. 

Stay updated: Website | Sign up for RNS alerts | Presentation | X | LinkedIn

Forward-Looking Statements

This announcement may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.

 

END